热门资讯> 正文
Oncolytics任命Jared Kelly为首席执行官
2025-06-11 19:46
- Oncolytics Biotech (NASDAQ:ONCY) has announced the appointment of Jared Kelly as CEO and a member of its Board of Directors.
- Most recently, he played a central role in orchestrating the sale of Ambrx Biopharma to Johnson & Johnson for $2B.
- "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." said Wayne Pisano, Chair of Oncolytics' Board of Directors and outgoing Interim CEO.
More on Oncolytics Biotech Inc.
- Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript
- Historical earnings data for Oncolytics Biotech Inc.
- Financial information for Oncolytics Biotech Inc.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
